Roche's Polivy ADC Is Approved As Another New Option For R/R DLBCL

The first-in-class anti-CD79b antibody-drug conjugate received a swift accelerated approval by the US FDA based on the results of a Phase Ib/II trial, for the same setting as CAR-T agents.